BioVie Inc clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company has developed a new drug candidate, BIV201 (continuous infusion terlipressin) and has completed a mid-stage Phase IIa clinical trial for treating ascites due to advanced liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The initial target for BIV201 therapy is refractory ascites, a serious complication of liver cirrhosis with an estimated 50% mortality rate within six to 12 months.